Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Deferred Revenue (2019 - 2023)

Fulcrum Therapeutics (FULC) has disclosed Current Deferred Revenue for 5 consecutive years, with $600000.0 as the latest value for Q3 2023.

  • Quarterly Current Deferred Revenue rose 50.0% to $600000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $600000.0 through Sep 2023, up 50.0% year-over-year, with the annual reading at $900000.0 for FY2022, 71.88% down from the prior year.
  • Current Deferred Revenue for Q3 2023 was $600000.0 at Fulcrum Therapeutics, up from $513000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $14.9 million in Q4 2020, with the low at $100000.0 in Q2 2022.
  • Average Current Deferred Revenue over 5 years is $4.1 million, with a median of $2.0 million recorded in 2021.
  • The sharpest move saw Current Deferred Revenue crashed 94.12% in 2022, then skyrocketed 413.0% in 2023.
  • Over 5 years, Current Deferred Revenue stood at $4.0 million in 2019, then soared by 273.78% to $14.9 million in 2020, then crashed by 78.54% to $3.2 million in 2021, then plummeted by 71.88% to $900000.0 in 2022, then plummeted by 33.33% to $600000.0 in 2023.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $600000.0, $513000.0, and $737000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.